camptothecin has been researched along with Pneumonia in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (30.77) | 29.6817 |
2010's | 3 (23.08) | 24.3611 |
2020's | 6 (46.15) | 2.80 |
Authors | Studies |
---|---|
Acharyya, S; Bazhenova, L; Cheng, Y; Felip, E; Goto, Y; Jänne, PA; Li, BT; Mazières, J; Nagasaka, M; Nakagawa, K; Pacheco, JM; Paz-Ares, L; Pérol, M; Planchard, D; Saltos, AN; Saxena, K; Shahidi, J; Shiga, R; Smit, EF; Udagawa, H; Vitazka, P | 1 |
Bako, E; Cathcart, J; Chiu, JWY; Chung, CF; Chung, WP; Cortés, J; Curigliano, G; Hamilton, E; Hegg, R; Huang, CS; Hurvitz, SA; Im, SA; Iwata, H; Kim, JH; Kim, MH; Kim, SB; Lee, C; Liu, Y; Park, YH; Pedrini, JL; Petry, V; Tseng, LM; Verma, S; Xu, B | 1 |
Andre, F; Bartholmai, BJ; Conte, P; Kato, T; Lancaster, LH; Li, BT; Naidoo, J; Nicholson, AG; Nishino, M; Powell, CA; Schumacher-Wulf, E; Shitara, K; Swain, SM; Tsurutani, J | 1 |
Abuhelwa, Z; Alloghbi, A; Alqahtani, A; Nagasaka, M | 1 |
Camidge, DR; Chang, DY; Iwata, H; Macpherson, E; Modi, S; Powell, CA; Qin, A; Shire, N; Siena, S; Singh, J; Smit, EF; Taitt, C; Takahashi, S | 1 |
Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C | 1 |
Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH | 1 |
Fukuda, H; Fukuoka, M; Kawahara, M; Kudoh, S; Nakagawa, K; Negoro, S; Saijo, N; Sawa, T; Semba, H; Takeda, K; Tanaka, M | 1 |
Gemma, A; Kakihata, K; Kon, A; Nagashima, M; Suzuki, T; Yoshii, N | 1 |
Ikehara, M; Noda, K; Nomura, I; Oshita, F; Tanaka, G; Yamada, K | 1 |
Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X | 1 |
Büscher, C; Fähndrich, S; Fietkau, R; Klautke, G; Semrau, S; Virchow, C | 1 |
3 review(s) available for camptothecin and Pneumonia
Article | Year |
---|---|
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Topics: Camptothecin; Humans; Immunoconjugates; Lung Diseases, Interstitial; Pneumonia; Trastuzumab | 2022 |
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
Topics: Adult; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2022 |
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2020 |
7 trial(s) available for camptothecin and Pneumonia
Article | Year |
---|---|
Trastuzumab Deruxtecan in
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Immunoconjugates; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pneumonia; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2022 |
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Middle Aged; Pneumonia; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2022 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Colitis; Dacarbazine; Diarrhea; Female; Humans; Irinotecan; Male; Neutropenia; Pneumonia; Recurrence; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Thrombocytopenia; Young Adult | 2009 |
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophagitis; Female; Humans; Incidence; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonia; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Severity of Illness Index | 2011 |
Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Treatment Outcome | 2004 |
Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Disease Progression; Dose Fractionation, Radiation; Esophagitis; Feasibility Studies; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pneumonia; Radiotherapy, Adjuvant; Remission Induction; Thrombocytopenia; Treatment Outcome | 2006 |
3 other study(ies) available for camptothecin and Pneumonia
Article | Year |
---|---|
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
Topics: Aged; Camptothecin; Humans; Immunoconjugates; Lung Diseases, Interstitial; Pneumonia; Retrospective Studies; Trastuzumab | 2022 |
Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Hypersensitivity; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasms; Pneumonia; Product Surveillance, Postmarketing; Pulmonary Alveoli; Steroids; Tomography, X-Ray Computed | 2011 |
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Topics: Analysis of Variance; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Length of Stay; Logistic Models; Lung; Male; Pneumonia; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Respiratory Distress Syndrome; Retrospective Studies; Sex Factors; Statistics, Nonparametric | 2006 |